These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 35677689)

  • 1. Mechanisms of Cardiorenal Protection With SGLT2 Inhibitors in Patients With T2DM Based on Network Pharmacology.
    Wang A; Li Z; Zhuo S; Gao F; Zhang H; Zhang Z; Ren G; Ma X
    Front Cardiovasc Med; 2022; 9():857952. PubMed ID: 35677689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Bioinformatics Investigation into the Pharmacological Mechanisms of Sodium-Glucose Co-transporter 2 Inhibitors in Diabetes Mellitus and Heart Failure Based on Network Pharmacology.
    Mai Z; Li H; Chen G; Chen E; Liu L; Lun Z; Lai W; Zhou C; Yu S; Liu J; Chen S; Chen J; Liu Y
    Cardiovasc Drugs Ther; 2022 Aug; 36(4):713-726. PubMed ID: 34028657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring the Mechanism of Cardiorenal Protection with Finerenone Based on Network Pharmacology.
    Si Y; Zhu Y; Liu J; Liu S; Cai X; Gu Y; Li H; Pan F; Wang W; Shangguan J; Liu R; Xi C; Wang L
    Cardiorenal Med; 2024; 14(1):334-349. PubMed ID: 38801815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SGLT2 Inhibition in Type 1 Diabetes with Diabetic Kidney Disease: Potential Cardiorenal Benefits Can Outweigh Preventable Risk of Diabetic Ketoacidosis.
    Liu H; Sridhar VS; Perkins BA; Rosenstock J; Cherney DZI
    Curr Diab Rep; 2022 Jul; 22(7):317-332. PubMed ID: 35633439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiorenal Syndrome in Type 2 Diabetes Mellitus - Rational Use of Sodium-glucose Cotransporter-2 Inhibitors.
    Kalra S; Aydin H; Sahay M; Ghosh S; Ruder S; Tiwaskar M; Kilov G; Kishor K; Nair T; Makkar V; Unnikrishnan AG; Dhanda D; Gupta N; Srinivasan B; Kumar A
    Eur Endocrinol; 2020 Oct; 16(2):113-121. PubMed ID: 33117442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors.
    Salvatore T; Galiero R; Caturano A; Rinaldi L; Di Martino A; Albanese G; Di Salvo J; Epifani R; Marfella R; Docimo G; Lettieri M; Sardu C; Sasso FC
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring the pharmacological components and effective mechanism of Mori Folium against periodontitis using network pharmacology and molecular docking.
    Wu Z; Ji X; Shan C; Song J; Zhao J
    Arch Oral Biol; 2022 Jul; 139():105391. PubMed ID: 35430443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiorenal protection with SGLT2 inhibitors in patients with diabetes mellitus: from biomarkers to clinical outcomes in heart failure and diabetic kidney disease.
    Liu H; Sridhar VS; Boulet J; Dharia A; Khan A; Lawler PR; Cherney DZI
    Metabolism; 2022 Jan; 126():154918. PubMed ID: 34699838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Network Pharmacology and Molecular Docking Study on the Potential Mechanism of Yi-Qi-Huo-Xue-Tong-Luo Formula in Treating Diabetic Peripheral Neuropathy.
    Lin Y; Shen C; Wang F; Fang Z; Shen G
    J Diabetes Res; 2021; 2021():9941791. PubMed ID: 34159207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological Mechanisms of Tinglizi against Chronic Heart Failure Determined by Network Pharmacology and Molecular Docking.
    Luo L; Wang H; Huang G; Zhang L; Li X; Ma C; Wang X
    Evid Based Complement Alternat Med; 2022; 2022():2152399. PubMed ID: 35035498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigating the Mechanisms of Pollen Typhae in the Treatment of Diabetic Retinopathy Based on Network Pharmacology and Molecular Docking.
    Zhou R; Jin D; Zhang Y; Duan L; Zhang Y; Duan Y; Kang X; Lian F
    Evid Based Complement Alternat Med; 2022; 2022():5728408. PubMed ID: 35024051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-Analysis on the Safety and Cardiorenal Efficacy of SGLT2 Inhibitors in Patients Without T2DM.
    Li LF; Ding LL; Zhan ZL; Qiu M
    Front Cardiovasc Med; 2021; 8():690529. PubMed ID: 34277737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular mechanism of Fufang Zhenzhu Tiaozhi capsule in the treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease based on network pharmacology and validation in minipigs.
    Wang H; Tan H; Zhan W; Song L; Zhang D; Chen X; Lin Z; Wang W; Yang Y; Wang L; Bei W; Guo J
    J Ethnopharmacol; 2021 Jun; 274():114056. PubMed ID: 33771638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors: Delving Into the Potential Benefits of Cardiorenal Protection Beyond the Treatment of Type-2 Diabetes Mellitus.
    Srinivas N; Sarnaik MK; Modi S; Pisipati Y; Vaidya S; Syed Gaggatur N; Sange AH; Sange I
    Cureus; 2021 Aug; 13(8):e16868. PubMed ID: 34513443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium-glucose cotransporter 2 inhibition in non-diabetic kidney disease.
    Almaimani M; Sridhar VS; Cherney DZI
    Curr Opin Nephrol Hypertens; 2021 Sep; 30(5):474-481. PubMed ID: 34074889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring the synergistic and complementary effects of berberine and paeoniflorin in the treatment of type 2 diabetes mellitus by network pharmacology.
    Zhang L; Han L; Ma J; Wu T; Wei Y; Zhao L; Tong X
    Eur J Pharmacol; 2022 Mar; 919():174769. PubMed ID: 35151646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Examining the effector mechanisms of Xuebijing injection on COVID-19 based on network pharmacology.
    Zheng WJ; Yan Q; Ni YS; Zhan SF; Yang LL; Zhuang HF; Liu XH; Jiang Y
    BioData Min; 2020; 13():17. PubMed ID: 33082858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring the Pleiotropic Genes and Therapeutic Targets Associated with Heart Failure and Chronic Kidney Disease by Integrating metaCCA and SGLT2 Inhibitors' Target Prediction.
    Li H; Mai Z; Yu S; Wang B; Lai W; Chen G; Zhou C; Liu J; Yang Y; Chen S; Liu Y; Chen J
    Biomed Res Int; 2021; 2021():4229194. PubMed ID: 34540994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic Target Analysis and Molecular Mechanism of Melatonin - Treated Leptin Resistance Induced Obesity: A Systematic Study of Network Pharmacology.
    Suriagandhi V; Nachiappan V
    Front Endocrinol (Lausanne); 2022; 13():927576. PubMed ID: 35937803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of SGLT2 inhibitors on haematocrit and haemoglobin levels and the associated cardiorenal benefits in T2DM patients: A meta-analysis.
    Tian Q; Guo K; Deng J; Zhong Y; Yang L
    J Cell Mol Med; 2022 Jan; 26(2):540-547. PubMed ID: 34878225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.